BCAL Diagnostics Issues Shares to Settle Service Provider Invoice

BCAL Diagnostics Limited ( (AU:BDX) ) has shared an update.

BCAL Diagnostics has applied to the ASX for quotation of 615,651 new fully paid ordinary shares issued on March 5, 2026. The shares arise from an agreement with a service provider to settle part of an invoice in equity, indicating the company is using scrip-based payments to manage cash outflows and preserve liquidity.

This equity-based settlement modestly increases BCAL Diagnostics’ share count and may slightly dilute existing shareholders while supporting the company’s operational commitments. The move underscores the firm’s continued reliance on capital markets and non-cash consideration as it advances its diagnostics activities and maintains relationships with key suppliers.

The most recent analyst rating on (AU:BDX) stock is a Hold with a A$0.11 price target. To see the full list of analyst forecasts on BCAL Diagnostics Limited stock, see the AU:BDX Stock Forecast page.

More about BCAL Diagnostics Limited

BCAL Diagnostics Limited is an Australian medical diagnostics company listed on the ASX under the code BDX. The company operates in the healthcare and life sciences sector, focusing on diagnostic technologies and related services for clinical and commercial partners.

Average Trading Volume: 276,515

Technical Sentiment Signal: Strong Buy

Current Market Cap: A$44.17M

See more insights into BDX stock on TipRanks’ Stock Analysis page.